Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide controlled release - Camurus

Drug Profile

Octreotide controlled release - Camurus

Alternative Names: CAM-2029; Octreotide chloride controlled release; Octreotide sc depot

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Camurus
  • Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acromegaly
  • Phase II Neuroendocrine tumours

Most Recent Events

  • 25 Jul 2019 Camurus initiates a phase III trial for Acromegaly in Hungary (SC) (EudraCT2019-001191-11 )
  • 12 Jul 2019 Phase-III clinical trials in Acromegaly in Hungary (SC) (EudraCT2019-002190-66)
  • 24 Jun 2019 The US FDA accepts IND application for phase III trial in Acromegaly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top